title: Yeast genetic screen reveals novel therapeutic strategy for ALS.
abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by a selective loss of motor neurons. There is no cure and few effective treatments. The RNA-binding protein TDP-43 contributes to the pathogenesis of ALS. TDP-43 is depleted from the nucleus and accumulates in cytoplasmic aggregates in the degenerating neurons and glia of most ALS patients. Furthermore, mutations in the TDP-43 gene cause rare familial and sporadic forms of the disease. Thus, therapeutic strategies targeting TDP-43 may be efficacious. We have used the yeast model system to identify the mechanisms by which TDP-43 aggregation contributes to ALS and to identify approaches to protect cells from the toxic effects of TDP-43 aggregation. Using an unbiased yeast genetic screen we discovered Dbr1 as a potent suppressor of TDP-43 toxicity. Yeast cells in which Dbr1 is deleted are resistant to TDP-43 toxicity. Dbr1 inhibition in mammalian cells is also sufficient to protect against TDP-43 cytotoxicity. Here, we review this recent discovery, highlighting future approaches aimed at extending these studies and pursuing Dbr1 as a novel therapeutic target for ALS.
authors.affiliation: Stanford Neuroscience Program, Stanford University School of Medicine, Stanford, CA ; Department of Genetics, Stanford University School of Medicine, Stanford, CA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Figley
authors.affiliation: Department of Genetics, Stanford University School of Medicine, Stanford, CA.
authors.forename: Aaron D
authors.initials: AD
authors.lastname: Gitler
keywords: ALS; Dbr1; TDP-43; neurodegeneration; yeast